Therapy of Urogenital Trichomoniasis

  • Joseph G. Lossick


Trichomonas vaginalis was discovered in 18361 and although it was known to cause vaginitis since 1916,2 a half-century passed before effective treatment was found for this common infection. During the interim period, the infection went untreated, occasionally resolved spontaneously, or it was treated with a variety of intravaginal preparations for long periods of time. These preparations, although helpful for some patients, were cumbersome to use for both patient and clinician, did not eradicate periurethral gland infections, and were unpredictably effective. A comparative study of some of these treatments revealed cure rates of only 22% to 40%.3 Also there was no treatment for trichomoniasis in the male. It became evident that a systemic treatment for this infection was needed.


Lactobacillus Phenobarbital Urticaria Barb Dithiocarbamate 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Donné MA : Animacules observes dans les ma-tières prurulentes et le produit des secretions des organes génitaux de l’homme et de la femme.C R Acad Sci (Paris) 3:385–386, 1836.Google Scholar
  2. 2.
    Hoehne O: Trichomonas vaginalis als häufiger Erreger einer typischen Colpitis purulenta. Zentralbl Gynäkol 40:40, 1916.Google Scholar
  3. 3.
    Clark DH, Solomons E, Siegal SA: Drugs for vaginal trichomoniasis: Results of a comparative study. Obstet Gynecol 20:615–620, 1962.PubMedGoogle Scholar
  4. 4.
    Despois R, Pinnert-Sindico S, Ninet L, Preud’ homme J: Three antibiotics of different groups produced by the same strain of streptomyces. J Microbiol 21:76–90, 1956.Google Scholar
  5. 5.
    Maeda K, Osato T, Umezawa H: A new antibiotic: Azomycin. J Antibiot 6A:182, 1953.Google Scholar
  6. 6.
    Cosar C, Julou L: Activité de l(2-hydroxy-ethyl)-2-methyl-5-nitroimidazole (8823 R.P.) vis-ä-vis des infections expérimentales ä Trichomonas vaginalis. Ann Inst Pasteur (Paris) 96:238–241, 1959.Google Scholar
  7. 7.
    Flagyl , a systemic trichomonacide. Med Lett 5:33–34, 1963.Google Scholar
  8. 8.
    DeCarneri I, Cantone A, Emanueli A, Giraldi PN, LogemannW, Meinardi C, Monti G, Nan-nini G, Tosolini G, Vita G: Nitrimidazine: A new systemic trichomonacide. In Proc Sixth Int Cong Chemother, Tokyo, Japan, 1969. In Umezawa H (ed): Progresss in Antimicrobial and Anticancer Chemotherapy 1:149–154, Baltimore: University Park Press, 1970.Google Scholar
  9. 9.
    Miller MS, Howes HL, English AR: Tinida-zole, a potent new antiprotozoal agent. Antimicrob Agents Chemother 1969:257–260, 1970.Google Scholar
  10. 10.
    Howes HL, Lynch JE, Kirlin JL: Tinidazole, a new antiprotozoal agent: Effect on Trichomonas and other protozoa. Antimicrob Agents Chemother 9:261–266, 1969.PubMedGoogle Scholar
  11. Müller M : Action of clinically utilized 5-nitroi-midazoles on microorganisms. Scand J Infect Dis (Suppl) 26:31–41, 1981.Google Scholar
  12. 12.
    Ings RMH, McFadzean JA, Ormerod WE: The mode of action of metronidazole in Trichomonas vaginalis and other micro-organisms. Biochem Pharmacol 23:1421–1429, 1974.PubMedCrossRefGoogle Scholar
  13. 13.
    Müller M, Lindmark DG: Uptake of metronidazole and its effects on viability in trichomonads and Entamoeba invadens under anaerobic and aerobic conditions. Antimicrob Agents Chemother 9:696–700, 1976.PubMedGoogle Scholar
  14. 14.
    Müller M, Gorrell TE: Metabolism and metronidazole uptake in Trichomonas vaginalis isolates with different metronidazole susceptibilities. Antimicrob Agents Chemother 24:667–673, 1983.PubMedGoogle Scholar
  15. 15.
    Lloyd D, Pedersen JZ: Metronidazole radical anion generation in vivo in Trichomonas vaginalis: Oxygen quenching is enhanced in a drug-resistant strain. J Gen Microbiol 131:87–92, 1985.PubMedGoogle Scholar
  16. 16.
    Nielsen MH : In vitro effect of metronidazole on the ultrastructure of Trichomonas vaginalis Donné. Acta Pathol Microbiol Scand (B)84:93–100, 1976.Google Scholar
  17. 17.
    Houghton GW, Smith J, Thorne PS, Tem-pleton R: The pharmacokinetics of oral and intravenous metronidazole in man. J Antimicrob Chemother 5:621–623, 1979.PubMedCrossRefGoogle Scholar
  18. 18.
    McGilveray IJ, Midha KK, Loo JC, Cooper JK: The bioavailability of commercial metronidazole formulations. Int J Clin Pharmacol Bio-pharm 16:110–115, 1978.Google Scholar
  19. 19.
    Urtasun RC, Sturmwind J, Rabin H, Band PR, Chapman JD:High dose, metronidazole: A preliminary pharmacological study prior to its investigational use in clinical radiotherapy trials. Br J Radiol 41:291–299, 1974.Google Scholar
  20. 20.
    Levison ME: Microbiological agar diffusion assay for metronidazole concentrations in serum. Antimicrob Agents Chemother 5:466–468, 1974.PubMedGoogle Scholar
  21. 21.
    Stambaugh JE, Feo LG, Manthei RW: The isolation and identification of the urinary oxidative metabolites of metronidazole in man. J Pharmacol Exp Ther 161:373–381, 1968.PubMedGoogle Scholar
  22. 22.
    Schwartz DE, Jeunet F: Comparative pharmacokinetic studies of ornidazole and metronidazole in man. Chemotherapy 22:19–29, 1976.PubMedCrossRefGoogle Scholar
  23. 23.
    Stambaugh JE, Feo LG, Manthei RW: Isolation and identification of the major urinary metabolites of metronidazole. Life Sci 6:1811–1819, 1967.PubMedCrossRefGoogle Scholar
  24. 24.
    Ralph ED, Kirby WM: Bioassay of metronidazole with either anaerobic or aerobic incubation. J Infect Dis 132:587–591, 1975.PubMedCrossRefGoogle Scholar
  25. 25.
    Bergman T: The pharmacokinetics of metronidazole. In Finegold SM (ed): Proc First US Metronidazole Conf Tarpon Springs, Florida, pp 83–111. New York: Biomedical Information Corporation, 1982.Google Scholar
  26. 26.
    Wood BA, Monro AM: Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses. Br J Vener Dis 51:51–53, 1975.PubMedGoogle Scholar
  27. 27.
    Ralph ED, Clarke JT, Libke RD, Luthy RP, Kirby WM: Pharmacokinetics of metronidazole as determined by bioassay. Antimicrob Agents Chemother 6:691–696, 1974.PubMedGoogle Scholar
  28. 28.
    Speck WT, Stein AB, Rosenkranz HS: Mutagenicity of metronidazole: Presence of several active metabolites in human urine. J. Natl Cancer Inst 56:283–284, 1976.PubMedGoogle Scholar
  29. 29.
    Koch RL, Beauliew BB, Chrystal EJT, Goldman, P: A metronidazole metabolite in human urine and its risk. Science 211:398–400, 1981.CrossRefGoogle Scholar
  30. 30.
    Gray MS, Kane PO, Squires S: Further observations on metronidazole (Flagyl). Br J Vener Dis 37:278–279, 1961.PubMedGoogle Scholar
  31. 31.
    Elder MG, Kane JL: The pelvic tissue levels achieved by metronidazole after single or multiple dosing—oral and rectal metronidazole. In Phillips I, Collier J (eds): Metronidazole: Proc Second Int Symp Anaerobic Infect, pp 55–58. London: The Royal Society of Medicine and Academic Press, 1979.Google Scholar
  32. 32.
    Davies AH: Metronidazole in human infections with syphilis. Br J Vener Dis 43:197–200, 1967.PubMedGoogle Scholar
  33. 33.
    Rood JP, Collier J: Metronidazole levels in alveolar bone. In Phillips I, Collier J (eds): Metronidazole: Proc Second Int Symp Anaerobic Infect, pp 45–47. London: The Royal Society of Medicine and Academic Press, 1979.Google Scholar
  34. 34.
    Nielsen ML, Justeson T: Excretion of metronidazole in human bile. Investigations of hepatic bile, common duct bile, and gallbladder bile. Scand J Gastroenterol 12:1003–1008, 1977.PubMedCrossRefGoogle Scholar
  35. 35.
    George RH, Bint AJ: Treatment of a brain abscess due to Bacteroides fragilis with metronidazole. J Antimicrob Chemother 2:101–102, 1976.PubMedCrossRefGoogle Scholar
  36. 36.
    Douglas-Smith BJ, Wellingham J: Metronidazole in treatment of empyema. Br Med J 1:1074–1075, 1976.CrossRefGoogle Scholar
  37. 37.
    Lossick JG: Metronidazole. N Engl J Med 304:735, 1981.PubMedGoogle Scholar
  38. 38.
    Davis B, Glover DD, Larsen B: Analysis of metronidazole penetration into vaginal fluid by reversed-phase high-performance liquid chromatography. Am J Obstet Gynecol 149:802–803, 1984.PubMedGoogle Scholar
  39. 39.
    Hofstad T, Sveen K: Penetration of metronidazole into preformed cavities in rabbits. J Antimicrob Chemother 6:275–278, 1980.PubMedCrossRefGoogle Scholar
  40. 40.
    Edwards DI, Thompson EJ, Tomusange J, Shanson D: Inactivation of metronidazole by aerobic organisms. J Antimicrob Chemother 5:315–316, 1979.PubMedCrossRefGoogle Scholar
  41. 41.
    Ingham HR, Hall CJ, Sisson PR, Tharagonnet D, Selkon JB: Inactivation of metronidazole by aerobic organisms. J Antimicrob Chemother 5:734–735, 1979.PubMedCrossRefGoogle Scholar
  42. 42.
    Mattila J, Männistö PT, Mäntylä R, Nykänen S, Lamminsivu U: Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob Agents Chemother 23:721–725, 1983.PubMedGoogle Scholar
  43. 43.
    Ioannides L, Somyogi A, Spicer J, Heinzow B, Tong N, Franklin C, McLean A: Rectal administration of metronidazole provides therapeutic plasma levels in postoperative patients. N Engl J Med 305:1569–1570, 1981.PubMedCrossRefGoogle Scholar
  44. 44.
    Opperman JA: Comparative disposition of 14-C-metronidazole after its oral and intravaginal administration to female subjects. Program & Abstracts 18th Intersci Conf Antimicrob Chemother, Atlanta, Georgia, 1978, Abstract 800. Wash DC: Am Soc Microbiol, 1978.Google Scholar
  45. 45.
    Alper MM, Bar win BN, McLean WM, McGil-veray I J, Sved S: Systemic absorption of metronidazole by the vaginal route. Obstet Gynecol 65:781–784, 1985.Google Scholar
  46. 46.
    Cerat GA, Cerat LL, McHenry MC, Wagner JG, Hall PM, Gaven TL: Metronidazole in renal failure. In Finegold SM (ed): Metronidazole: Proc Int Metronidazole Conf pp 404–414. Amsterdam: Excerpta Medica, 1977.Google Scholar
  47. 47.
    Gabriel R, Page CM, Collier J, Houghton GW, Templeton R, Thorne PS: Removal of metronidazole by haemodialysis. Br J Surg 67:553, 1980.PubMedCrossRefGoogle Scholar
  48. 48.
    Cassey JG, Clark DA, Merrick P, Jones B: Pharmacokinetics of metronidazole in patients undergoing peritoneal dialysis. Antimicrob Agents Chemother 24:950–951, 1983.PubMedGoogle Scholar
  49. 49.
    Guay DR, Weatherall RC, Baxter H, Jacyk WR, Penner B: Pharmacokinetics of metronidazole in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 25:306–310, 1984.PubMedGoogle Scholar
  50. 50.
    Kreeft JH, Ogilvie RI, Dufresne LR: Metronidazole kinetics in dialysis patients. Surgery 93:149–153, 1983.PubMedGoogle Scholar
  51. 51.
    Bergan T, Bjerke PE, Fausa O: Pharmacokinetics of metronidazole in patients with enteric disease compared to normal volunteers. Chemotherapy 27:233–238, 1981.PubMedCrossRefGoogle Scholar
  52. 52.
    Mead PB, Gibson M, Schentag J J, Ziemniak JA: Possible alteration of metronidazole metabolism by phenobarbital. N Engl J Med 306:1490, 1982.PubMedGoogle Scholar
  53. 53.
    Gupte S: Phenobarbital and metabolism of metronidazole. N Engl J Med 308:529, 1983.PubMedGoogle Scholar
  54. 54.
    Gugler G, Jensen JC: Interaction between Cimetidine and metronidazole. N Engl J Med 309:1518–1519, 1983.PubMedCrossRefGoogle Scholar
  55. 55.
    Pereyra M, Chipping PM, Noone P: Intravenous metronidazole in the treatment and prophylaxis of anaerobic infection. J Antimicrob Chemother 6:105–112, 1980.CrossRefGoogle Scholar
  56. 56.
    Placidi GF, Masuoka D, Alcaraz A, Taylor JAT, Earle R: Distribution and metabolism of 14C-metronidazole in mice. Arch Int Pharma-codyn Ther 188:168–179, 1970.Google Scholar
  57. 57.
    Hager WD, Brown ST, Kraus SJ, Kleris GS, Perkins GJ, Henderson M: Metronidazole for vaginal trichomoniasis: Seven-day vs single-dose regimens. JAMA 244:1219–1220, 1980.PubMedCrossRefGoogle Scholar
  58. 58.
    Csonka GW: Longterm aspect of treatment with metronidazole (Flagyl) in trichomonal vaginitis. Br J Vener Dis 39:258–260, 1963.PubMedGoogle Scholar
  59. 59.
    Rodin P, King AJ, Nicol CS, Barrow J: Flagyl in the treatment of trichomoniasis. Br J Vener Dis 36:147–151, 1960.PubMedGoogle Scholar
  60. 60.
    Roe JFC: A critical appraisal of the toxicology of metronidazole. In Phillips I, Collier J (eds): Metronidazole: Proc Second Int Symp Anaerobic Infect, pp 215–222. London: The Royal Society of Medicine and Academic Press, 1979.Google Scholar
  61. 61.
    Frytak S, Moertel CE, Childs DS, Albers JW: Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 88:361–362, 1978.PubMedGoogle Scholar
  62. 62.
    Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ: Central nervous system toxicity associated with metronidazole therapy. Ann Intern Med 93:59–60, 1980.PubMedGoogle Scholar
  63. 63.
    George WL, Kirby BD, Sutter VL, Wheeler LA, Mulligan ME, Finegold SM: Intravenous metronidazole for treatment of infections involving anaerobic bacteria. Antimicrob Agents Chemother 21:441–449, 1982.PubMedGoogle Scholar
  64. 64.
    Dainer MH: Untoward reaction to Flagyl (metronidazole). Am J Obstet Gynecol 133: 939–940, 1979.PubMedGoogle Scholar
  65. 65.
    Winter D, Stänescu C, Sauverd E: The effect of metronidazole on the toxicity of ethanol. Biochem Pharmacol 18:1246–1248, 1969.PubMedCrossRefGoogle Scholar
  66. 66.
    Iyer KS, Kutty AG: Influence of metronidazole and chloral hydrate on the activity of other drugs. Indian J Physiol Pharmacol 18:49–51, 1974.PubMedGoogle Scholar
  67. 67.
    O’Reilly RA: Sterospecific interaction of warfarin and metronidazole. Fed Proc 34:259, 1975.Google Scholar
  68. 68.
    Brandt LJ, Bernstein LH, Boley SJ, Frank MS: Metronidazole therapy for perineal Crohn’s disease: A follow-up study. Gastroenterology 83:383–387, 1982.PubMedGoogle Scholar
  69. 69.
    Jensen JC, Gugler R: Single and multiple-dose metronidazole kinetics. Clin Pharmacol Ther 34:481–487, 1983.PubMedCrossRefGoogle Scholar
  70. 70.
    Voogd CE, Van Der Stel JJ, Jacobs JAA: The mutagenic action of nitroimidazoles. I. Metronidazole, nimorazole, dimetridazole and roni-dazole. Mutat Res 26:483–490, 1974.PubMedCrossRefGoogle Scholar
  71. 71.
    Legator MS, Conner TH, Stoeckel M: Detection of mutagenic activity of metronidazole and niridazole in body fluids of humans and mice. Science 188:1118–1119, 1975.PubMedCrossRefGoogle Scholar
  72. 72.
    Conner TH, Stoeckel M, Evrard J, Legator MS: The contribution of metronidazole and two metabolites to the mutagenic activity detected in urine in treated humans and mice. Cancer Res 37:629–633, 1977.Google Scholar
  73. 73.
    Rust JH: An assessment of metronidazole tu-morigenicity: Studies in mouse and rat. In Fine-gold SM (ed): Metronidazole: Proc Int Metronidazole Conf pp 138–144. Amsterdam: Excerpta Medica, 1977.Google Scholar
  74. 74.
    Rustia M, Shubik P: Experimental induction of hepatomas, mammary tumors, and other tumors with metronidazole in noninbred Sas: MRC(WI)BR rats. J Natl Cancer Inst 63:863–868, 1979.PubMedGoogle Scholar
  75. 75.
    Rustia M, Shubik P: Induction of lung tumors and malignant lymphomas in mice by metronidazole. JNatl Cancer Inst 48:721–729, 1972.Google Scholar
  76. 76.
    Mitelmann F, Hartley ASPB, Ursing B: Chromosome aberrations and metronidazole. Lancet 2:802, 1976.CrossRefGoogle Scholar
  77. 77.
    Mitelmann F, Strömbeck B, Ursing B: No cyto-genic effect of metronidazole. Lancet 1:1249–1250, 1980.CrossRefGoogle Scholar
  78. 78.
    Lambert B, Lindblad A, Ringborg U: Absence of genotoxic effects of metronidazole and two of its urinary metabolites on human lymphocytes in vitro. Mutat Res 26:483–490, 1974.CrossRefGoogle Scholar
  79. 79.
    Bost RG: Metronidazole: Toxicology and teratology. In Finegold SM (ed): Metronidazole: Proc Int Metronidazole Conf pp 112–117. Amsterdam: Excerpta Medica, 1977.Google Scholar
  80. 80.
    Ivanov I: The effect of ‘‘Trichomonicid” on pregnancy in experimental animals. Akush Ginekol 8:241–244, 1969.Google Scholar
  81. 81.
    Cella PL: Experimental studies on the teratology of metronidazole. Riv Patol Clin 24:529–537, 1969.Google Scholar
  82. 82.
    Sands RX: Pregnancy, trichomoniasis, and metronidazole: A novel dose schedule. Am J Obstet Gynecol 94:350–353, 1966.PubMedGoogle Scholar
  83. 83.
    Perl G: Metronidazole treatment of trichomoniasis in pregnancy. Obstet Gynecol 25:273–276, 1965.PubMedGoogle Scholar
  84. 84.
    Rodin P, Hass G: Metronidazole and pregnancy. Br J Vener Dis 42:210–212, 1966.PubMedGoogle Scholar
  85. 85.
    Morgan I: Metronidazole in pregnancy. Int J Gynaecol Obstet 15:501–502, 1978.PubMedGoogle Scholar
  86. 86.
    Peterson WF, Stauch JE, Ryder CO: Metronidazole in pregnancy. Am J Obstet Gynecol 94:343–349, 1966.Google Scholar
  87. 87.
    Beard MC, Noller KL, O’Fallon WM, Kurk-land LT, Dockerty MB: Lack of evidence for cancer due to use of metronidazole. N Engl J Med 301:519–522, 1979. Friedman GD: Cancer after metronidazole. N Engl J Med 302:519, 1980.Google Scholar
  88. Friedman GD: Cancer after metronidazole. N Engl J Med 302:519, 1980.Google Scholar
  89. 89.
    Danielson DA, Hannan MT, Jick H: Metronidazole and cancer. JAMA 247:2498–2499, 1982.PubMedCrossRefGoogle Scholar
  90. 90.
    Beard MC: Cancer after metronidazole. N Engl J Med 302:520, 1980.CrossRefGoogle Scholar
  91. 91.
    Beard MC, Noller KL, OTallon WM: Metronidazole and subsequent malignant neoplasms. In Proc 18th Meet Soc Epidemiol Res, Chapel Hill, NC, June 1985, Am J Epidemiol 122:529, 1988.Google Scholar
  92. 92.
    Koss IG, Wolinska WH: Trichomonas vaginalis cervicitis and its relationship to cervical cancer. Cancer 12:1171–1193, 1959.PubMedCrossRefGoogle Scholar
  93. 93.
    Simeckova M, Lonser E, Nicholas EE, Ru-benstein I: Chronic trichomoniasis and cervical cancer. Obstet Gynecol 20:410–412, 1962.PubMedGoogle Scholar
  94. 94.
    Lindmark DG, Müller M: Antitrichomonal action, mutagenicity and reduction of metronidazole and other nitroimidazoles. Antimicrob Agents Chemother 10:476–482, 1976.PubMedGoogle Scholar
  95. 95.
    Lossick JG: Treatment of Trichomonas vaginalis infections. Rev Infect Dis 4(suppl):5801–5818, 1982.Google Scholar
  96. 96.
    Lyng J, Christensen J: A double-blind study of the value of treatment with a single dose tinidazole of partners to females with trichomoniasis. Acta Obstet Gynecol Scand 60:199–201, 1981.PubMedGoogle Scholar
  97. 97.
    Sköld M, Gnarpe H, Hillström L: Ornidazole: A new antiprotozoal compound for the treatment of Trichomonas vaginalis infections. Br J Vener Dis 53:44–48, 1977.PubMedGoogle Scholar
  98. 98.
    Videau D, Niel G, Siboulet A, Catalan F: Sec-nidazole. A 5-nitroimidazole with a long half-life. Br J Vener Dis 54:77–80, 1978.PubMedGoogle Scholar
  99. 99.
    Sawyer PA, Brodgen RN, Pinder RM: Tinidazole: A review of its antiprotozoal activity and therapeutic efficacy. Drugs 2:423–440, 1976.CrossRefGoogle Scholar
  100. 100.
    Hillström L, Pettersson L, Pälsson E, Sandström SO: Comparison of ornidazole and tinidazole in single-dose treatment of trichomoniasis in women. Br J Vener Dis 53:193–194, 1977.PubMedGoogle Scholar
  101. 101.
    Tinkler AE: Nimorazole compared to metronidazole in the treatment of vaginal trichomoniasis. Practitioner 212:115–119, 1974.PubMedGoogle Scholar
  102. 102.
    Wigfield AS: Trichomonal vaginitis: A 24 hour regimen of nimorazole compared to a 7-day regimen of metronidazole. Br J Vener Dis 51:54–56, 1975.PubMedGoogle Scholar
  103. 103.
    Hayward MJ, Roy RB: Two-day treatment of trichomoniasis in the female: Comparison of metronidazole and nimorazole. Br J Vener Dis 52:63–64, 1976.PubMedGoogle Scholar
  104. 104.
    Weidenbach A, Leix H: Treatment of trichomonal vaginitis with a single dose of tinidazole. Curr Med Res Opin 2:147–152, 1974.PubMedCrossRefGoogle Scholar
  105. 105.
    Mahony JDH, Harris JRW, Farrer CJ: Nimorazole and metronidazole in the treatment of trichomonal vaginitis. Br J Clin Pract 29:71–72, 1975.PubMedGoogle Scholar
  106. 106.
    Chaudhuri P, Drogendijk AC: A double-blind controlled clinical trial of carnidazole and tinidazole in the treatment of vaginal trichomoniasis. Eur J Obstet Gynecol Reprod Biol 10:325–328, 1980.PubMedCrossRefGoogle Scholar
  107. 107.
    Salem AR, Jackson DD, McFadzean JA: An investigation of interactions between metronidazole (‘‘Flagyl”) and other antibacterial agents. J Antimicrob Chemother 1:387–391, 1975.PubMedCrossRefGoogle Scholar
  108. 108.
    Ralph ED, Amatnieks YE: Potentially synergistic antimicrobial combinations with metronidazole against Bacteroides fragilis. Antimicrob Agents Chemother 17:379–382, 1980.PubMedGoogle Scholar
  109. 109.
    Amon K, Amon I, Muller H: Maternal-fetal passage of metronidazole. In Hejzlar M, Sem-onsky M, Masak S (eds): Advances in Antimicrobial Antineoplastic Chemotherapy, vol 1/1, pp 113–115. Baltimore: University Park Press, 1972.Google Scholar
  110. 110.
    Schnell JD: The incidence of vaginal Candida and Trichomonas infections and treatment of Trichomonas vaginitis with clotrimazole. Postgrad Med J 50(suppl 1):79–81, 1974.PubMedGoogle Scholar
  111. 111.
    Legal HP : The treatment of trichomoniasis and Candida vaginitis with clotrimazole vaginal tablets. Postgrad Med J 50:(suppl l):81–83, 1974.PubMedGoogle Scholar
  112. 112.
    Lohmeyer H : Treatment of candidiasis and trichomoniasis of the female genital tract. Postgrad Med J 50(suppl l):78–79, 1974.PubMedGoogle Scholar
  113. 113.
    Trussell RE, Wilson ME, Longwell FH, Laugh-lin KA: Vaginal trichomoniasis: Complement fixation, puerperal morbidity, and early infection of newborn infants. Am J Obstet Gynecol 44:292, 1942.Google Scholar
  114. 114.
    Farouk L, Salihi A, Curran JP: Neonatal Trichomonas vaginalis: Report of three cases and a review of the literature. Pediatrics 53:196–200, 1974.Google Scholar
  115. 115.
    Erickson SH, Oppenheim GL, Smith GH: Metronidazole in breast milk. Obstet Gynecol 57:48–50, 1981.PubMedGoogle Scholar
  116. 116.
    Korner B, Jensen HK: Sensitivity of Trichomonas vaginalis to metronidazole, tinidazole, and nifuratel in vitro. Br J Vener Dis 52:404–408, 1976.PubMedGoogle Scholar
  117. 117.
    Krieger JN, Dickins CS, Rein MF: Use of a time-kill technique for susceptibility testing of Trichomonas vaginalis. Antimicrob Agents Chemother 27:332–336, 1985.PubMedGoogle Scholar
  118. 118.
    Meingassner JG, Mieth H, Czok R, Lindmark DG, Müller M: Assay conditions and the demonstration of nitroimidazole resistance in Tritrichomonas foetus. Antimicrob Agents Chemother 13:1–3, 1978.PubMedGoogle Scholar
  119. 119.
    Meingassner JG, Thurner J: Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles. Antimicrob Agents Chemother 15:254–257, 1979.PubMedGoogle Scholar
  120. 120.
    Müller M, Meingassner JG, Miller WA, Ledger WJ: Three metronidazole-resistant strains of Trichomonas vaginalis from the United States. Am J Obstet Gynecol 138:808–812, 1980.PubMedGoogle Scholar
  121. 121.
    Smith RF, DiDomenico A: Measuring the in vitro susceptibility of Trichomonas vaginalis to metronidazole. Sex Transm Dis 7:120–124, 1980.PubMedCrossRefGoogle Scholar
  122. 122.
    McFadzean JA, Pugh IM, Squires SL, Whelan JPF: Further observations on strain sensitivity of Trichomonas vaginalis to metronidazole. Br J Vener Dis 45:161–162, 1969.PubMedGoogle Scholar
  123. 123.
    Nielsen R: Trichomonas vaginalis. II. Laboratory investigations in trichomoniasis. Br J Vener Dis 49:531–535, 1973.Google Scholar
  124. 124.
    Müller M, Gorrell TE, Lossick JG: Metronidazole susceptibility of Trichomonas vaginalis and results of treatment. Proc 83rd Ann Meet Am Soc Microbiol, New Orleans, March 6–11, 1983, p 9. Washington DC: American Society for Microbiology.Google Scholar
  125. 125.
    Ralph ED, Darwish R, Austin TW, Smith EA, Pattison FLM: Susceptibility of Trichomonas vaginalis strains to metronidazole: Response to treatment. Sex Transm Dis 10:119–122, 1983.PubMedCrossRefGoogle Scholar
  126. 126.
    Meingassner JG, Stockinger K: Untersuchungen zur Identifikation metronidazolresistenter Trichomonas vaginalis-Stämme in vitro. ZHautkr 56:7–15, 1981.Google Scholar
  127. 127.
    Meingassner JG : Comparative studies on the trichomonacidal activity of 5-nitroimidazole derivatives in mice infected s.c. or intravagi-nally with T. vaginalis. Experientia 33:1160–1161, 1977.PubMedCrossRefGoogle Scholar
  128. 128.
    Asami K: Effects of metronidazole on Trichomonas vaginalis in culture and in an experimental host. Am J Trop Med Hyg 12:535–538, 1963.PubMedGoogle Scholar
  129. 129.
    Michaels RM, Peterson LJ, Stahl GL: Substituted dithiocarbamates and related compounds as trichomonacides. J Pharm Pharmacol 15: 107–113, 1963.PubMedCrossRefGoogle Scholar
  130. 130.
    Cuckler AC, Kupferberg AB, Millman N: Chemotherapeutic and tolerance studies of amino-nitro-thiazoles. Antibiot Chemother 5:540–550, 1955.Google Scholar
  131. 131.
    Street DA, Taylor-Robinson D, Hetherington CM: Infection of squirrel monkeys (Saimiri sciureus) with Trichomonas vaginalis as a model of trichomoniasis in women. Br J Vener Dis 59:249–254, 1983.PubMedGoogle Scholar
  132. 132.
    Benazet F, Gullaume L: Activités antiami-bienne et trichomonacide du secnidazole au la-boratoire. Bull Soc Pathol Exot Filiales 69:309–319, 1976.PubMedGoogle Scholar
  133. 133.
    Richie R, Scholer HJ, Angehrn P, Fernex M.,Hummler H, Jeunet F, Schärer K, Schüpach K, Schwartz DE: Grundlagen der chemotherapie von trichomoniasis und amoebiasis mit ornida-zole. Arzneim-Forsch 28:612–625, 1978.Google Scholar
  134. 134.
    Meingassner JG, Havelec L, Mieth H: Studies on strain sensitivity of Trichomonas vaginalis to metronidazole. Br J Vener Dis 54:72–76, 1978.PubMedGoogle Scholar
  135. 135.
    Tsai YH, Price KE: Experimental models for the evaluation of systemic trichomonacides. Chemotherapy 18:348–357, 1973.PubMedCrossRefGoogle Scholar
  136. 136.
    Robinson SC: Trichomonal vaginitis resistant to metronidazole. Can Med Assoc J 86:665, 1962.PubMedGoogle Scholar
  137. 137.
    Pereyra AJ, Lansing JD: Urogenital trichomoniasis: Treatment with metronidazole in 2,002 incarcerated women. Obstet Gynecol 24:499–508, 1964.PubMedGoogle Scholar
  138. 138.
    Diddle AW: Trichomonas vaginalis: Resistance to metronidazole. Am J Obstet Gynecol 98:583–584, 1967.PubMedGoogle Scholar
  139. 139.
    de Carneri I, Achilli G, Mont G, Trane F: Induction of in-vivo resistance of Trichomonas vaginalis to metronidazole. Lancet 2:1308–1309, 1969.PubMedCrossRefGoogle Scholar
  140. 140.
    Forsgren A, Forsmann L: Metronidazole resistant Trichomonas vaginalis. Br J Vener Dis 55:351–353, 1979.PubMedGoogle Scholar
  141. 141.
    Heyworth R, Simpson D, McNeillage GJ, Robertson DH, Young H: Isolation of Trichomonas vaginalis resistant to metronidazole. Lancet 2:476–478, 1980.PubMedCrossRefGoogle Scholar
  142. 142.
    Mattern CFT, Spence MR, Navovitz PC: Properties of metronidazole resistant Trichomonas vaginalis: Possible therapeutic approaches. Program & Abstracts 21st Intersci Conf Antimicrob Agents Chemother, Chicago, Illinois, 1981. Abstract No. 766, Washington DC: American Society for Microbiology, 1981.Google Scholar
  143. 143.
    Waitkins SA, Thomas DJ: Isolation of Trichomonas vaginalis resistant to metronidazole. Lancet 2:590, 1981.PubMedCrossRefGoogle Scholar
  144. 144.
    Kulda J, Vojtechovskä M, Tachezy J, Demes P, Kunzovä E: Metronidazole resistance of Trichomonas vaginalis as a cause of treatment failure in trichomoniasis—A case report. Br J Vener Dis 58:394–399, 1982.PubMedGoogle Scholar
  145. 145.
    Lossick JG, Müller M, Gorrell TE: In vitro drug susceptibility and dosages required for cure in metronidazole resistant vaginal trichomoniasis. J Infect Dis 153:948–955, 1986.PubMedCrossRefGoogle Scholar
  146. 146.
    Matheson I, Hernborg Johannessen K, Bjork-voll B: Plasma levels after a single dose of 1.5 g ornidazole. Br J Vener Dis 53:236–239, 1977.PubMedGoogle Scholar
  147. 147.
    Notowicz A, Stolz E, DeKoning GAF: First experiences with single-dose treatment of vaginal trichomoniasis with carnidazole (R 25831). Br J Vener Dis 53:129–131, 1977.PubMedGoogle Scholar
  148. 148.
    Taylor JA, Migliardi JR, Schach von Wittenau M: Tinidazole and metronidazole pharmacokinetics in man and mouse. Antimicrob Agents Chemother 10:267–270, 1970. Ripa T, Weström L, Mardh PA, Anderson KE: Concentrations of tinidazole in body fluids and tissues in gynaecological patients. Chemotherapy 23:227–235, 1977.Google Scholar
  149. 149.
    Ripa T. Weström L. Mårdh PA, Anderson KE: Concentrations of tinidazole in vody fluids and tissues in gynaecological patients. Chemotherapy 23:227–235, 1977.PubMedCrossRefGoogle Scholar
  150. 150.
    Nilsson-Ehle I, Ursing B, Nilsson-Ehle P: Liquid chromatographic assay for metronidazole and tinidazole: Pharmacokinetic and metabolic studies in human subjects. Antimicrob Agents Chemother 19:754–760, 1981.PubMedGoogle Scholar
  151. 151.
    Ray DK, Chatterjee DK, Tendulkar JS: Comparative efficacy of Go 10213 and some nitro-imidazoles against Trichomonas vaginalis and T foetus in mice infected subcutaneously. Ann Trop Med Parasitol 76:175–178, 1982.PubMedGoogle Scholar
  152. 152.
    Fowler W, Hussain M: Nifuratel (Magmilor) in trichomonal vaginitis. Br J Vener Dis 44:331–333, 1968.PubMedGoogle Scholar
  153. 153.
    Evans BA, Catterall RD: Nifuratel compared to metronidazole in the treatment of trichomonal vaginitis. Br Med J 1:335–336, 1970.CrossRefGoogle Scholar
  154. 154.
    Pathak UN, Sur SK, Farrand RS: Comparison of metronidazole/nystatin and nitrofuratel in the treatment of vaginitis. Br J Clin Pract 29:270–272, 1975.PubMedGoogle Scholar
  155. 155.
    Ripmann ET: SolcoTrichovac in medical practice: An open multicentre study to investigate the antitrichomonal vaccine SolcoTrichovac. Gynäkol Rundsch 23(suppl 2):77–84, 1983.CrossRefGoogle Scholar
  156. 156.
    Elokda HH, Andrial M: The therapeutic and prophylactic efficacy of SolcoTrichovac in women with trichomoniasis: Investigations in Cairo. Gynäkol Rundsch 23(suppl 2):85–88, 1983.PubMedCrossRefGoogle Scholar
  157. 157.
    Litschgi M: SolcoTrichovac in the prophylaxis of trichomonad reinfection: A randomized double-blind study. Gynäkol Rundsch 23(suppl 2):72–76, 1983.PubMedCrossRefGoogle Scholar
  158. 158.
    Hatala M, Kejda J, Kveton J, Liska M: SolcoTrichovac in the treatment of vaginitis episodes. Abstracts Int Symp Trichomonads & Trichomoniasis, Prague, July 1985, p 68. Prague: Local Organizing Comm, Dept Parasitol, Faculty Sci, Charles Univ, 1985.Google Scholar
  159. 159.
    Stojkovic L, Bossart W: A Lactobacillus acidophilus inactivated vaccine active against trichomoniasis in women: Some experimental data. Abstracts Int Symp Trichomonads & Trichomoniasis, Prague, July 1985, p 63. Prague: Local Organizing Comm, Dept Parasitol, Faculty Sci, Charles Univ, 1985.Google Scholar
  160. 160.
    Gombosovä A, Demes P, Valent M: Immu-notherapeutic effect of the Lactobacillus vaccine SolcoTrichovac in trichomoniasis is not mediated by cross-reacting antibodies against Trichomonas vaginalis. Abstracts Int Symp Trichomonads & Trichomoniasis, Prague, July 1985, p 65. Prague: Local Organizing Comm, Dept Parasitol, Faculty Sci, Charles Univ, 1985.Google Scholar
  161. 161.
    Lorgren T, Salmela I: In vitro sensitivity of Trichomonas vaginalis and Candia albicans to chemotherapeutic agents. Acta Pathol Microbiol Scand 86:155–158, 1978.Google Scholar
  162. 162.
    Meingassner JG, Heyworth PG: Intestinal and urogenital flagellates. Antibiot Chemother 30:163–202, 1981.PubMedGoogle Scholar
  163. 163.
    Paredes FR, Hawkins DF: Sensitivity of Trichomonas vaginalis to chemotherapeutic agents. J Obstet Gynaecol Br Commonw 80:86–88, 1973.PubMedCrossRefGoogle Scholar
  164. 164.
    Bruckner DA, Bueding E, Voge M: Lack of obligatory association between mutagenic and antitrichomonal effects of metronidazole. J Parasitol 65:473–474, 1979.PubMedCrossRefGoogle Scholar
  165. 165.
    Cantelli-Forti G, Aicardi G, Guerra MC, Barb-aro AM, Biagi GL: Mutagenicity of a series of 25 nitroimidazoles and two nitrothiazoles in Salmonella typhimurium. Teratog Carcinog Mutagen 3:51–63, 1983.PubMedCrossRefGoogle Scholar
  166. 166.
    Meingassner JG, Mieth H: Cross-resistance of trichomonads to 5-nitroimidazole derivatives. Experientia 32:183–184, 1976.PubMedCrossRefGoogle Scholar
  167. 167.
    Ray DK, Tendulkar JS, Shrivastava VB, Datta AK, Nagarajan K: A metronidazole-resistant strain of Trichomonas vaginalis and its sensitivity to Go 10213. J Antimicrob Chemother 14:423–425, 1984.PubMedCrossRefGoogle Scholar
  168. 168.
    Kawamura N: Studies on Trichomonas vaginalis in the urological field. Pt. I–V. Jpn J Urol 60:15–49, 1969.Google Scholar
  169. 169.
    Kawamura N: Studies on Trichomonas vaginalis in the urological field. VI. Clinical efficacy of various drugs. Jpn J Urol 64:281–286, 1973.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1990

Authors and Affiliations

  • Joseph G. Lossick

There are no affiliations available

Personalised recommendations